$130 Million is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 18 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 72.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSHA | Sell | TAYSHA GENE THERAPIES INC | $29,493,000 | -33.3% | 1,391,190 | -36.2% | 22.62% | -12.8% |
| VT | Sell | VANGUARD TOTAL WORLD STOCK ETFetfs | $16,421,000 | -0.7% | 158,484 | -6.8% | 12.60% | +29.8% |
| AGLE | Sell | AEGLEA BIOTHERAPEUTICS INC | $1,876,000 | -15.3% | 269,578 | -3.6% | 1.44% | +10.7% |
| PG | Exit | PROCTER & GAMBLE CO/THE | $0 | – | -20 | -100.0% | -0.00% | – |
| AMZN | Exit | AMAZON.COM INC | $0 | – | -3 | -100.0% | -0.01% | – |
| TPL | Exit | TEXAS PACIFIC LAND CORP | $0 | – | -16 | -100.0% | -0.02% | – |
| UPS | Exit | UNITED PARCEL SERVICE CL-B | $0 | – | -200 | -100.0% | -0.02% | – |
| FB | Exit | FACEBOOK INC | $0 | – | -180 | -100.0% | -0.03% | – |
| DNLI | Exit | DENALI THERAPEUTICS INC | $0 | – | -23,629 | -100.0% | -0.79% | – |
| VIR | Exit | VIR BIOTECHNOLOGY INC | $0 | – | -94,513 | -100.0% | -2.84% | – |
| ACCD | Exit | ACCOLADE INC | $0 | – | -1,191,326 | -100.0% | -31.71% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
| PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
| LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
| AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
| APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
| PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
| VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
| VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
| VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
| VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
| ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4/A | 2024-05-14 |
| 4 | 2024-05-01 |
| 3 | 2024-04-30 |
| 13F-HR | 2024-04-30 |
| 144 | 2024-04-29 |
| SC 13G | 2024-03-05 |
| 13F-HR | 2024-02-28 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-04 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.